Antagonists of luteinizing hormone-releasing hormone (LH-RH), unlike the LH-RH agonists, suppress gonadotropins and sex steroid secretion immediately after administration, without initial stimulatory effects. [Ac-DNal(2)1,D-Ph(4C1)2,D-Pal(3)3,D-Cit6,D-Ala"]LH-RH Cetrorelix) is a modern, potent antagonistic analog of LH-RH. In this study, the binding characteristics of receptors for LH-RH in membrane fractions from rat anterior pituitaries were investigated after a single injection of Cetrorelix at a dose of 100 ,ug per rat. More than 20 years have passed since the isolation, determination of structure, and synthesis of the hypothalamic hormone controlling the secretion of both luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the anterior pituitary (1). In the past 2 decades, >3000 agonists and antagonists of this decapeptide, called luteinizing hormonereleasing hormone (LH-RH) have been synthesized in view of their expected therapeutic applications (2-4). While repeated chronic administration of LH-RH agonists is required to induce a suppression of LH and FSH and reduction in the levels of sex steroids, similar effects can be obtained after a single injection of LH-RH antagonists (2-7). During the past few years, several highly potent antagonistic analogs of LH-RH containing neutral amino acids D-citrulline or D-homocitrulline at positions 6 and free of edematogenic and anaphylactoid reactions were synthesized by our group and tested in vitro and
receptors were significantly (P < 0.01) down-regulated for at least 72 h after administration of Cetrorelix. The lowest receptor concentration was found 3-6 h after Cetrorelix treatment and a recovery in receptor number began within -24 h. The down-regulation of LH-RH binding sites induced by Cetrorelix was accompanied by serum LH and testosterone suppression. Higher LH-RH receptor concentrations coincided with elevated serum hormone levels at later time intervals. Our results indicate that administration of LH-RH antagonist Cetrorelix produces a marked down-regulation of pituitary receptors for LH-RH and not merely an occupancy of binding sites.
More than 20 years have passed since the isolation, determination of structure, and synthesis of the hypothalamic hormone controlling the secretion of both luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the anterior pituitary (1) . In the past 2 decades, >3000 agonists and antagonists of this decapeptide, called luteinizing hormonereleasing hormone (LH-RH) have been synthesized in view of their expected therapeutic applications (2) (3) (4) . While repeated chronic administration of LH-RH agonists is required to induce a suppression of LH and FSH and reduction in the levels of sex steroids, similar effects can be obtained after a single injection of LH-RH antagonists (2) (3) (4) (5) (6) (7) . During the past few years, several highly potent antagonistic analogs of LH-RH containing neutral amino acids D-citrulline or D-homocitrulline at positions 6 and free of edematogenic and anaphylactoid reactions were synthesized by our group and tested in vitro and
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It is well established that chronic administration of LH-RH agonists reduces the number of pituitary receptors for LH-RH, a phenomenon that has been called down-regulation, and induces desensitization of the pituitary gonadotrophs (2-4, 10, 11) . Although the principal mechanism of action of LH-RH antagonists was thought to be the competitive blockade of LH-RH receptors, recent data indicate that prolonged treatment with potent LH-RH antagonist Cetrorelix also downregulates pituitary LH-RH receptors in rats (12) (13) (14) (15) .
The purpose of this study was to investigate the binding characteristics of receptors for LH-RH in membrane fractions from rat anterior pituitaries after a single injection of Cetrorelix. The pattern of changes in number and affinity of receptors for LH-RH was defined after administration of Cetrorelix followed by in vitro desaturation of LH-RH antagonist from its receptors by chaotropic agents, such as manganous chloride (MnCl2) and ammonium thiocyanate (NH4SCN) (16, 17) . The use of such techniques allows estimation of total LH-RH receptor concentration and not only of measurable free receptors. The timing of receptor events after administration of Cetrorelix was compared with the sequel of inhibitory effects on gonadotropin and sex steroid secretion in male rats. in the untreated control group ( Table 2 ). The lowest Bmax values were found 3-6 h after Cetrorelix treatment, but the LH-RH receptors were still detectable. The concentration of receptors of LH-RH was down-regulated significantly (P < 0.01) for at least 72 h ( Table 2 ). The time course of Cetrorelixinduced decrease in LH-RH receptor levels showed that a recovery in receptor number began within -24 h and continued for the period of the study. The concentration of receptors increased markedly at 48 h and the levels at 72 h were even higher. However, the number of receptors at 72 h was still significantly lower than those in controls. Kd values were not altered significantly, except that 6 h after the treatment there was a slight increase in affinity. Our results clearly demonstrate the down-regulation of LH-RH receptors and not merely an occupancy of LH-RH binding sites by LH-RH antagonist Cetrorelix.
MATERIALS AND METHODS

Chemicals. LH-
Serum LH and Testosterone Levels. The fall in LH and sex steroid levels after administration of LH-RH antagonists was previously demonstrated by us and other investigators (5, 7, 8, 14, 15) . However, we thought that it would be important to examine the timing of the fall in LH and testosterone levels following Cetrorelix administration under the conditions of our experiment aimed at receptors. Serum LH and testosterone levels in rats injected with Cetrorelix are shown in Table  3 . Serum LH levels were significantly suppressed by Cetrorelix for 72 h, as compared to the control group (0.93 ± 0.18 ng/ml).
The maximal suppression was seen 3 and 6 h after injection, with nadir values of 0.20 ± 0.04 ng/ml and 0.20 ± 0.06, respectively. Forty-eight hours after Cetrorelix administration, LH concentrations increased slightly and reached '50% of the control value. Serum testosterone levels were also significantly (P < 0.01) suppressed after administration of Cetrorelix. Twenty-four hours after injection of 100 ,ug of Cetrorelix, serum testosterone fell below the detection limit of the RIA (0.20 ng/ml). Testosterone levels then increased to 2.55 ± 0.32 ng/ml at 48 h and remained in that range for at least another 24 h. However, 72 h after Cetrorelix administration, serum LH and testosterone were still significantly below normal levels. The patterns of the decline and the recovery of the pituitary receptors for LH-RH and serum LH levels are shown in Fig. 2 . DISCUSSION LH-RH antagonists were originally designed and synthesized for contraception (3, 4) . However, a variety of experimental work and, more recently, clinical studies indicate that LH-RH antagonists can be used for the treatment of sex steroiddependent or -sensitive tumors and other conditions in which inhibition of steroid secretion is desirable (3, 4, 6, 8, (26) (27) (28) (29) . The use of antagonistic analogs of LH-RH would avoid transient stimulation of the release of gonadotropins and sex steroids, which occurs initially in response to LH-RH agonists, thus preventing the temporary clinical flare-up of the disease (4, 27) . Among these antagonists, Cetrorelix has been shown to be one of the most powerful (5, 9) . LH-RH antagonists act on the same receptor sites as LH-RH and produce an immediate inhibition of the release of LH, FSH, and sex steroids (3, 4, 6, 7, 9, 14, 15, 26, 29) . The mode of action of LH-RH antagonists varies in some aspects from that of the agonists inasmuch as down-regulation of receptors is not required for an inhibitory effect, which is immediate, due to occupancy of receptors (12, 30) . Nevertheless, recent evidence from our laboratory showed that prolonged treatment with modem LH-RH antagonist Cetrorelix causes a marked down-regulation of pituitary LH-RH receptors in rats (12, 14, 15) . Those results are in agreement with findings made in other laboratories (13) . This down-regulation of pituitary LH-RH receptors is reversible and a complete recovery occurs 2-5 months after cessation of treatment (14, 15) . Previous studies which did not show that this down-regulation occurs, were done with early, weak antagonists and/or injected in inadequate doses (31) . Clinical studies in normal subjects and patients with benign prostate hyperplasia (BPH) and prostate cancer show protracted suppression of LH and testosterone levels by Cetrorelix and suggest that the receptor down-regulation could also occur in men (4, (27) (28) (29) This study also revealed that the down-regulation of pituitary LH-RH receptors induced by Cetrorelix in the first 24 h after administration is accompanied by the fall in serum LH and testosterone levels. The reduction in LH levels clearly paralleled a decrease in receptor numbers (Fig. 2) . At later time periods a recovery occurs in receptor concentrations and serum hormone levels and both rise markedly. However, normal levels of receptors and serum LH and testosterone are not achieved for more than 72 h. Our results indicate that administration of potent LH-RH antagonists like Cetrorelix to rats produces a marked down-regulation of receptors for LH-RH in pituitary and not merely an occupancy of LH-RH binding sites. A similar down-regulation may occur also in men (4, 27, 28) . The down-regulation of pituitary LH-RH receptors by LH-RH antagonists in other species and the internalization of bound antagonist-receptor complex need further investigation. In conclusion, the treatment with LH-RH antagonist, similarly to that with the LH-RH agonists, appears to lead to down-regulation of pituitary LH-RH receptors, contrary to previous views (33) . These phenomena might have clinical relevance for planning therapy with LH-RH antagonists.
